Valeant Pharmaceuticals Intl Inc (VRX) : Quantitative Investment Management added new position in Valeant Pharmaceuticals Intl Inc during the most recent quarter end. The investment management firm now holds 981,900 shares of Valeant Pharmaceuticals Intl Inc which is valued at $29,348,991 , the company said in a statement filed on May 2, 2016 with the SEC.Valeant Pharmaceuticals Intl Inc makes up approximately 1.39% of Quantitative Investment Management’s portfolio.
Valeant Pharmaceuticals Intl Inc closed down -4.6 points or -13.34% at $29.89 with 3,64,36,855 shares getting traded on Friday. Post opening the session at $33.18, the shares hit an intraday low of $29.8 and an intraday high of $33.83 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Agf Investments added VRX to its portfolio by purchasing 3,985 company shares during the most recent quarter which is valued at $119,112.Glenmede Trust Co Na reduced its stake in VRX by selling 480 shares or 19.42% in the most recent quarter. The Hedge Fund company now holds 1,992 shares of VRX which is valued at $66,453. Friedberg Investment Management sold out all of its stake in VRX during the most recent quarter. The investment firm sold 34,363 shares of VRX which is valued $1,146,350.Metlife Securities Inc boosted its stake in VRX in the latest quarter, The investment management firm added 4,333 additional shares and now holds a total of 6,842 shares of Valeant Pharmaceuticals Intl Inc which is valued at $246,175. Valeant Pharmaceuticals Intl Inc makes up approx 0.01% of Metlife Securities Inc’s portfolio. Highstreet Asset Management sold out all of its stake in VRX during the most recent quarter. The investment firm sold 361 shares of VRX which is valued $12,989.
On the company’s financial health, Valeant Pharmaceuticals Intl Inc reported $2.50 EPS for the quarter, missing the analyst consensus estimate by $ -0.12 based on the information available during the earnings call on Mar 15, 2016. Analyst had a consensus of $2.62. The company had revenue of $2788.70 million for the quarter, compared to analysts expectations of $2762.59 million. The company’s revenue was up 22.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.58 EPS.
Many Wall Street Analysts have commented on Valeant Pharmaceuticals Intl Inc. Shares were Reiterated by Rodman & Renshaw on May 3, 2016 to “Buy” and Lowered the Price Target to $ 102 from a previous price target of $105 .Shares were Reiterated by RBC Capital Mkts on Apr 12, 2016 to “Sector Perform” and Lowered the Price Target to $ 65 from a previous price target of $69 .Shares were Reiterated by Rodman & Renshaw on Apr 11, 2016 to “Buy” and Lowered the Price Target to $ 105 from a previous price target of $118 .
Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.